Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$11.00 USD

11.00
5,599,789

+1.80 (19.57%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $11.00 0.00 (0.00%) 5:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review

by Zacks Equity Research

Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.

Pieris (PIRS) Up On Receiving Milestone Payment From Partner

by Zacks Equity Research

Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.

Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study

by Zacks Equity Research

Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.

Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.

Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More

by Kinjel Shah

Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.

Sundeep Ganoria headshot

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

by Sundeep Ganoria

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -8.94% and 65.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod

by Zacks Equity Research

Emergent's (EBS) shares rise as its anthrax vaccine, Cyfendus (AV7909), gets FDA approval, offering preventive measures for people aged 18 to 65, who were exposed to the harmful bacillus anthracis germ.

Emergent Biosolutions (EBS) Moves 6.4% Higher: Will This Strength Last?

by Zacks Equity Research

Emergent Biosolutions (EBS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for May 17th

by Zacks Equity Research

BIDU, EBS and FRO have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2023.

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray

by Zacks Equity Research

ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.

Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.

Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More

by Kinjel Shah

Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Is ALPS International Sector Dividend Dogs ETF (IDOG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IDOG

Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why

by Zacks Equity Research

Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.

Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose

by Zacks Equity Research

Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.

Emergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.